Adding venetoclax to standard transplant conditioning
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether adding a drug called venetoclax to a standard transplant preparation regimen (called treosulfan-based reduced intensity conditioning) can improve the success of a stem cell transplant for patients with certain blood cancers like AML, MDS/AML, or high-risk MDS. The goal is to see if this combination makes the transplant safer and more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and can give informed consent in German.
- You have been diagnosed with AML, MDS/AML, or high-risk MDS (according to specific classification systems).
- Your disease must be under control (e.g., achieved a certain level of response after chemotherapy) or have slow-growing disease.
- You are eligible for a stem cell transplant using peripheral blood stem cells, and you have a suitable donor (either a matched sibling or a matched unrelated donor).
- Your heart, lungs, liver, and kidney function must meet the study's thresholds (e.g., heart pump function ≥40%, lung function tests within limits, kidney function above a certain level).
- You must not have certain active infections (like HIV, hepatitis B/C, or a fungal infection) or a history of prior stem cell transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding venetoclax to standard chemotherapy to help people with newly diagnosed acute myeloid leukemia (AML) or high-risk MDS (MDS-EB-2) live longer and reduce cancer activity. You may benefit if you’re eligible for intensive chemotherapy and meet specific blood, organ, and treatment timing requirements.
This trial tests adding venetoclax to a standard “conditioning” chemotherapy plan before an allogeneic stem cell transplant (using a donor) for certain bone marrow cancers. It aims to improve how well the transplant works and how safe this combination is for people with MDS, CMML, or sAML.
This trial tests adding venetoclax to the usual chemotherapy (fludarabine and melphalan) given before a stem cell transplant for older adults with AML or MDS. The goal is to see if the combination helps prevent the disease from coming back after transplant.
This trial tests whether adding venetoclax (a pill that targets cancer cells) to the standard chemotherapy regimen before a stem cell transplant improves outcomes for people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). It is for patients aged 12–60 whose cancer has specific high-risk features and who have a matched donor.
This trial tests whether adding the targeted drug venetoclax to intensive chemotherapy works better for different types of AML. It is for people aged 14 to 60 who are newly diagnosed and have not received prior treatment.
This trial combines three standard chemotherapy drugs (fludarabine, cytarabine, idarubicin) with a targeted therapy (venetoclax) to treat acute myeloid leukemia (AML) and a related condition called MDS with high blast counts. The goal is to see if adding venetoclax improves results.
Hear when a new MDS (Myelodysplastic Syndrome) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.